Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population
- 24 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (9) , 716-721
Abstract
Aims: Lipoprotein(a) (Lp(a)) levels are known to be mainly genetically determined. However, only scarce data are available on the intra-individual variability of Lp(a) levels across time. Methods and results: We included adult patients (≥18 years old) who had baseline and follow-up Lp(a) measurements (between 1997 and 2024) with a minimum of 1 year apart. Patients were categorized into three groups as follows: normal (<30 mg/dL), borderline (30 to 50 mg/dL), and high Lp(a) (≥50 mg/dL). Multivariable logistic regression was conducted to assess the predictors of the intra-individual changes in Lp(a) ≥ 10 mg/dL. A total of 11 669 individuals (median age: 54 years, 60% males) were included in our analysis, with median time between measurements of 4.5 years [interquartile range (IQR): 2.2, 10.6]. The median Lp(a) was 16 mg/dL (IQR: 7, 52) at baseline, compared with 15 mg/dL (IQR: 7, 52) at follow-up. At follow-up, 96.4% of individuals with normal Lp(a) and 89.9% with high Lp(a) remained in their categories, while 51.2% with borderline Lp(a) changed their category. Of the included population, 24.9% had an intra-individual Lp(a) change ≥ 10 mg/dL. Female sex (P < 0.001), history of ASCVD (P = 0.003), statin therapy (P = 0.003), and elevated LDL cholesterol (LDL-C) levels ≥ 100 mg/dL (P < 0.001) were significantly associated with higher odds of intra-individual Lp(a) changes ≥ 10 mg/dL. Conclusion: Lipoprotein(a) levels were generally stable over time; however, patients with borderline levels may require more than one Lp(a) measurement, especially if they are females, have a history of ASCVD, have elevated LDL-C levels, or are on statin therapy.Keywords
This publication has 11 references indexed in Scilit:
- A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practiceJournal of Clinical Lipidology, 2024
- Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severityEuropean Journal of Preventive Cardiology, 2024
- Lipoprotein(a), platelet function and cardiovascular diseaseNature Reviews Cardiology, 2023
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statementEuropean Heart Journal, 2022
- Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population StudyAtherosclerosis, 2022
- Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular RiskJACC, 2022
- Finding very high lipoprotein(a): the need for routine assessmentEuropean Journal of Preventive Cardiology, 2021
- Statin therapy increases lipoprotein(a) levelsEuropean Heart Journal, 2019
- Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsDrugs, 2018
- Whether, to what degree, and why lipoprotein(a) levels change over timeClinica Chimica Acta, 1995